These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 3552204

  • 1. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial.
    Struck RF, Alberts DS, Horne K, Phillips JG, Peng YM, Roe DJ.
    Cancer Res; 1987 May 15; 47(10):2723-6. PubMed ID: 3552204
    [Abstract] [Full Text] [Related]

  • 2. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
    Sladek NE, Doeden D, Powers JF, Krivit W.
    Cancer Treat Rep; 1984 Oct 15; 68(10):1247-54. PubMed ID: 6395951
    [Abstract] [Full Text] [Related]

  • 3. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
    Struck RF, Alberts DS.
    Cancer Treat Rep; 1984 May 15; 68(5):765-70. PubMed ID: 6722832
    [Abstract] [Full Text] [Related]

  • 4. Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508.
    Chan KK, Hong PS, Tutsch K, Trump DL.
    Cancer Res; 1994 Dec 15; 54(24):6421-9. PubMed ID: 7987837
    [Abstract] [Full Text] [Related]

  • 5. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
    Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy MJ, Strong JM.
    Clin Cancer Res; 1996 Sep 15; 2(9):1481-7. PubMed ID: 9816324
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
    Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M.
    Eur J Cancer; 2011 Jul 15; 47(10):1556-63. PubMed ID: 21482104
    [Abstract] [Full Text] [Related]

  • 7. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL, Kennedy MJ, Anderson LW, Kiraly SB, Black KC, Colvin OM, Grochow LB.
    Drug Metab Dispos; 1997 May 15; 25(5):544-51. PubMed ID: 9152592
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
    Momerency G, Van Cauwenberghe K, Slee PH, Van Oosterom AT, De Bruijn EA.
    Biol Mass Spectrom; 1994 Mar 15; 23(3):149-58. PubMed ID: 8148406
    [Abstract] [Full Text] [Related]

  • 10. Cytotoxic activity relative to 4-hydroxycyclophosphamide and phosphoramide mustard concentrations in the plasma of cyclophosphamide-treated rats.
    Powers JF, Sladek NE.
    Cancer Res; 1983 Mar 15; 43(3):1101-6. PubMed ID: 6825082
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B, Pokorny R, Kovarik JM, Duffy FA, Willemse PH, Mulder NH, de Vries EG.
    Cancer Res; 1993 Dec 15; 53(24):5915-9. PubMed ID: 8261403
    [Abstract] [Full Text] [Related]

  • 12. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
    Jardine I, Fenselau C, Appler M, Kan MN, Brundrett RB, Colvin M.
    Cancer Res; 1978 Feb 15; 38(2):408-15. PubMed ID: 620410
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
    Hong PS, Srigritsanapol A, Chan KK.
    Drug Metab Dispos; 1991 Feb 15; 19(1):1-7. PubMed ID: 1673381
    [Abstract] [Full Text] [Related]

  • 14. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
    de Jonge ME, Huitema AD, van Dam SM, Rodenhuis S, Beijnen JH.
    Ther Drug Monit; 2005 Dec 15; 27(6):756-65. PubMed ID: 16306851
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
    Kroschinsky FP, Friedrichsen K, Mueller J, Pursche S, Haenel M, Prondzinsky R, Ehninger G, Schleyer E.
    Cancer Chemother Pharmacol; 2008 Apr 15; 61(5):785-90. PubMed ID: 17579865
    [Abstract] [Full Text] [Related]

  • 16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 15; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 17. Vomiting induced by cyclophosphamide and phosphoramide mustard in cats.
    Fetting JH, McCarthy LE, Borison HL, Colvin M.
    Cancer Treat Rep; 1982 Aug 15; 66(8):1625-9. PubMed ID: 7105052
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.
    Ramanathan-Girish S, Catz P, Creek MR, Wu B, Thomas D, Krogstad DJ, De D, Mirsalis JC, Green CE.
    Int J Toxicol; 2004 Aug 15; 23(3):179-89. PubMed ID: 15204721
    [Abstract] [Full Text] [Related]

  • 19. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study.
    Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R.
    Arthritis Rheum; 1998 Oct 15; 41(10):1835-44. PubMed ID: 9778225
    [Abstract] [Full Text] [Related]

  • 20. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients.
    Hadidi AH, Coulter CE, Idle JR.
    Cancer Res; 1988 Sep 15; 48(18):5167-71. PubMed ID: 3409242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.